Recent evidence, from us and others, revealed that mineralocorticoid receptor (MR) blockade attenuates obesity and diabetes-associated CMD in preclinical models [4, 7] and patients [19, 33] independent of blood pressure. The gene discussed is NR3C2; the disease is obesity due to melanocortin 4 receptor deficiency.